about
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegansApoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesGenome-environment interactions that modulate aging: powerful targets for drug discoveryTargeting melanoma by small molecules: challenges aheadStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewChem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology dataTargeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modelingAurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.Bifunctional Lipocalin Ameliorates Murine Immune Complex-induced Acute Lung InjurySystems biology approaches for advancing the discovery of effective drug combinationsA yeast phenomic model for the gene interaction network modulating CFTR-ΔF508 protein biogenesis.Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyCombination therapeutics in complex diseasesSanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current UsesIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesHalofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1Deciphering diseases and biological targets for environmental chemicals using toxicogenomics networksOptimal drug synergy in antimicrobial treatmentsMitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drugSynergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice modelAnti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerPooled screening for synergistic interactions subject to blocking and noiseEvodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoproteinSynergistic and antagonistic drug combinations depend on network topologyStudy on the main components interaction from Flos Lonicerae and Fructus Forsythiae and their dissolution in vitro and intestinal absorption in ratsA modularity-based method reveals mixed modules from chemical-gene heterogeneous networkA Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial ResultsSystems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General CaseSimulating Serial-Target Antibacterial Drug Synergies Using Flux Balance AnalysisNetwork-based drug discovery by integrating systems biology and computational technologiesExploiting genomic knowledge in optimising molecular breeding programmes: algorithms from evolutionary computingDistribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discoveryNon-monotonic dynamics and crosstalk in signaling pathways and their implications for pharmacologyTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionTinnitus: network pathophysiology-network pharmacology.Not Just a Sum? Identifying Different Types of Interplay between Constituents in Combined InterventionsA strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines.Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation.Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
P2860
Q21144448-59A5C8F2-6D20-41FC-8196-474AB244EC17Q21245649-4C8DF5DE-9E73-4A87-9E2F-07290AB74282Q24289511-BDC2BCE3-9640-4428-BF0A-C35E8B2D4E7CQ24615803-FF8FB42D-3475-47AD-B2AF-A5BF5220DFA9Q26824642-3A90188A-A348-45A1-8F9A-39FBF817C3F6Q27008867-16673C34-98A4-48F1-9E31-CC47ECD954E4Q27136634-384B6A22-AB45-49B1-8FD6-079E647AAD15Q27334339-905E9BBB-7455-4695-B77C-CEE42E5B1FFDQ27346432-DAD6B747-65AE-4B41-8E6A-E436DCE75B53Q27677832-A6A475EA-6BB2-40ED-A3A9-AB2B5DAE6308Q27702922-E71DEE37-E383-41E8-AF1A-4C751434A130Q27931694-4755B4C1-EFB5-4A83-98D5-FAA8CB92181DQ28076097-17CD10EC-340D-4CC7-80F8-458CB56E7CB6Q28076891-3BF8F603-DDD9-47DA-B26A-3AFAA425460CQ28077612-B9D9E99A-F383-4DED-B27A-5A266C6134D3Q28388335-0917DB5C-D7E2-476F-9234-13191D2EFD18Q28468670-C38FC668-4C1C-454C-A602-E725F2570EEDQ28473983-C060492A-404B-4649-87D2-D710F2CDB093Q28474170-0BC70787-75FB-4398-B58C-FD067A79CB1DQ28478861-E1FDF1B4-ABF0-42EF-9644-41AD06D8AB34Q28484057-D93F02E3-5587-485B-BFF3-324A56A9E714Q28534413-00598D53-B8E9-47D2-B5B6-E9A8CBC724A4Q28538785-5BF5C214-34F4-49E7-95D0-30106927ED9AQ28538867-C734F1BD-085B-4429-A153-D611B3D4CF71Q28542101-7D6A5CA4-2A0B-4B99-BFE4-009EF18485CAQ28543513-F0FD098D-F270-4694-8C2B-39B5BB65A559Q28546883-ACE32A38-9A65-4956-8115-BF2FDB8B60D0Q28547962-793A5924-0AE5-40A3-84D2-854D835B864EQ28550867-21689064-2732-48CD-8B12-306238AFC0A9Q28552960-245ACDB8-5261-46F6-8A13-D2F8CAC034FAQ28677268-417F97A5-7EB6-4357-9176-EE8AA3EBDE2BQ28710543-443609A1-A580-4253-8D25-F36E92106618Q28754659-EBA8AC92-CCEA-4141-B5E6-AC3B292810D2Q28817451-F5305242-3D5D-4433-A7AA-F409D8446395Q29617359-AFCF6B64-09F0-4FDE-A969-713AF10897F9Q30412371-89DE3536-8829-4A5D-B1F8-F9B224F9A8A9Q30650188-D7F7BDEC-D3A7-4679-AEFE-78553C4F8686Q30658500-3C958A02-DF0D-446D-A37D-41AA6289E4ABQ30885749-E5547986-B026-4CEA-91CB-7730D4286E27Q33229063-82CEB7F2-4FDD-4B22-8AF6-6B63963004A1
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Multicomponent therapeutics for networked systems.
@ast
Multicomponent therapeutics for networked systems.
@en
Multicomponent therapeutics for networked systems.
@nl
type
label
Multicomponent therapeutics for networked systems.
@ast
Multicomponent therapeutics for networked systems.
@en
Multicomponent therapeutics for networked systems.
@nl
prefLabel
Multicomponent therapeutics for networked systems.
@ast
Multicomponent therapeutics for networked systems.
@en
Multicomponent therapeutics for networked systems.
@nl
P2093
P2860
P356
P1476
Multicomponent therapeutics for networked systems.
@en
P2093
Alexis A Borisy
Brent R Stockwell
Curtis T Keith
P2860
P2888
P356
10.1038/NRD1609
P577
2005-01-01T00:00:00Z